FDA Approves Mannkind's At-Home Treatment for Heart Failure and Kidney Disease
The U.S. Food and Drug Administration has approved Furoscix ReadyFlow, an at-home treatment developed by MannKind Corporation (MNKD) to manage edema in adults with heart failure or chronic kidney disease. This is the first autoinjector delivering IV-equivalent exposure of furosemide, offering a patient-friendly format that administers a full 80 mg/mL dose within seconds and may reduce emergency interventions. MannKind also announced a $50 million private placement financing to support corporate operations and fulfill a contingent payment tied to the FDA approval. The company's stock is currently trading at $4.20, above its short-term moving averages but with weakening momentum as indicated by technical indicators like MACD below its signal line. Heart failure affects 6.7 million U.S. adults today and is expected to rise to over 8 million by 2030, highlighting the potential market size for Furoscix ReadyFlow.
Tickers: $MNKD
Topics: chronic kidney disease heart failure treatment pharmaceuticals